Sanofi Options First Recursion Candidate for $10 Million Milestone
Recursion Pharmaceuticals announced on October 15, 2026 that Sanofi has optioned the first development candidate from the two companies' multi-program research collaboration, triggering a US$10 million milestone payment to Recursion and advancing a potential first-in-class oral small molecule in immunology into Sanofi's development pipeline. The option exercise brought total upfront and milestone payments received from Sanofi under the collaboration to $144 million, according to the company…